Profile data is unavailable for this security.
About the company
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
- Revenue in USD (TTM)4.01m
- Net income in USD-214.53m
- Incorporated2008
- Employees290.00
- LocationCrinetics Pharmaceuticals Inc10222 Barnes Canyon Rd Bldg 2SAN DIEGO 92121-2711United StatesUSA
- Phone+1 (858) 450-6464
- Fax+1 (302) 636-5454
- Websitehttps://www.crinetics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MoonLake Immunotherapeutics | 0.00 | -36.01m | 3.21bn | 50.00 | -- | 6.13 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Ideaya Biosciences Inc | 23.38m | -112.96m | 3.23bn | 124.00 | -- | 4.54 | -- | 138.09 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.24bn | 251.00 | -- | 3.49 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
Azenta Inc | 641.02m | -17.37m | 3.31bn | 3.50k | -- | 1.36 | 47.41 | 5.17 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Neogen Corp | 918.68m | 11.78m | 3.35bn | 2.64k | 284.19 | 1.06 | 26.59 | 3.64 | 0.0544 | 0.0544 | 4.24 | 14.54 | 0.2005 | 3.06 | 6.27 | 347,985.20 | 0.257 | 3.44 | 0.2666 | 3.62 | 50.58 | 47.25 | 1.28 | 7.77 | 2.63 | 1.45 | 0.2203 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Hims & Hers Health Inc | 872.00m | -23.55m | 3.37bn | 1.05k | -- | 9.77 | -- | 3.87 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
Simply Good Foods Co | 1.25bn | 133.28m | 3.38bn | 271.00 | 25.67 | 2.10 | 21.94 | 2.71 | 1.32 | 1.32 | 12.39 | 16.10 | 0.5943 | 6.41 | 8.49 | 4,614,288.00 | 6.33 | 3.66 | 6.58 | 3.83 | 36.59 | 38.90 | 10.66 | 6.80 | 3.46 | 7.78 | 0.1448 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
Alvotech SA | 93.38m | -551.73m | 3.38bn | 999.00 | -- | -- | -- | 36.23 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.46bn | 290.00 | -- | 5.62 | -- | 862.80 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.50bn | 517.00 | -- | 21.74 | -- | 8.77 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 3.56bn | 525.00 | -- | 19.23 | -- | 19.57 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Fortrea Holdings Inc | 3.11bn | -3.40m | 3.58bn | 18.00k | -- | 2.05 | 38.53 | 1.15 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Immunitybio Inc | 622.00k | -583.20m | 3.68bn | 628.00 | -- | -- | -- | 5,916.04 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
SpringWorks Therapeutics Inc | 5.45m | -325.10m | 3.70bn | 305.00 | -- | 5.88 | -- | 678.67 | -5.14 | -5.14 | 0.0862 | 8.52 | 0.008 | -- | -- | 17,859.02 | -47.95 | -36.97 | -53.00 | -39.49 | 92.25 | -- | -5,968.50 | -2,176.46 | 6.37 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
Arcellx Inc | 110.32m | -70.69m | 3.72bn | 130.00 | -- | 7.59 | -- | 33.72 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Axsome Therapeutics Inc | 270.60m | -239.24m | 3.75bn | 545.00 | -- | 19.63 | -- | 13.86 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
Holder | Shares | % Held |
---|---|---|
Driehaus Capital Management LLCas of 31 Dec 2023 | 5.04m | 7.55% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 4.80m | 7.19% |
EcoR1 Capital, LLCas of 28 Feb 2024 | 3.91m | 5.86% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.69m | 5.52% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.56m | 5.34% |
Point72 Asset Management LPas of 31 Dec 2023 | 3.42m | 5.12% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.40m | 5.09% |
Wellington Management Co. LLPas of 31 Dec 2023 | 3.25m | 4.86% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.94m | 4.41% |
Jennison Associates LLCas of 31 Dec 2023 | 2.55m | 3.81% |